Abstract
Inflammation and oxidative stress contribute to numerous human diseases. Conventional therapies provide symptomatic relief but fail to address molecular dysfunction. Cannabinoids emerge as promising modulators of these processes, influencing CB1/2 receptor signaling, regulating NF-κB and Nrf2 pathways, and reactive oxygen species production. Preclinical studies demonstrate them to reduce cytokine release, limit oxidative damage, and protect tissue integrity across multiple systems. Early clinical investigations suggest potential benefits in pain management, neurodegeneration, and metabolic conditions. Future research focusing on minor and synthetic cannabinoids, biomarker-guided dosing, and combination therapies can enhance translational success, but regulatory and safety considerations remain critical. By bridging mechanistic insights with clinical application, cannabinoids hold significant potential to address diseases driven by inflammation and oxidative stress and to expand therapeutic landscape.